Jeanette Weidner, Principal Accounting Officer and Principal Financial Officer of Gain Therapeutics, Inc., filed a Form 4 on October 30, 2026, disclosing the acquisition of stock options covering 130,000 shares of common stock on October 29, 2026.

Key Highlights

  • Option grant: Weidner acquired a stock option (right to buy) covering 130,000 shares of Gain Therapeutics common stock on October 29, 2026.
  • Exercise price: The option carries an exercise price of $1.19 per share.
  • Price paid: The filing reports the price of the derivative security as $0.00.
  • Expiration date: The option expires on October 29, 2036.
  • Vesting schedule: 25% of the underlying shares vest on October 29, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to continuous service through each vesting date.
  • Resulting ownership: Following the transaction, Weidner beneficially owns 130,000 derivative securities, held directly.

Weidner Option Award Details at Gain Therapeutics

According to the Form 4 filed with the U.S. Securities and Exchange Commission on October 30, 2026, Jeanette Weidner, identified in the filing as Principal Accounting Officer and Principal Financial Officer of Gain Therapeutics, Inc. (NASDAQ:GANX), reported the acquisition of a stock option to purchase 130,000 shares of the company's common stock. The transaction date is listed as October 29, 2026, and the transaction code is recorded as "A," indicating an acquisition.

The filing reports the exercise price of the option at $1.19 per share and the price of the derivative security at $0.00. The option is set to expire on October 29, 2036. As described in the explanation of responses, "The shares underlying the Option shall vest as to 25% on October 29, 2027, and the remainder shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."

No Table I non-derivative securities transactions were reported in this filing. Following the reported transaction, Weidner beneficially owns 130,000 derivative securities on a direct basis, according to the filing. The form was filed by one reporting person, with Weidner's address listed as c/o Gain Therapeutics, Inc., 4800 Montgomery Lane, Suite 220, Bethesda, Maryland 20814.

What Was Disclosed

The filing discloses a stock option grant of 130,000 shares at an exercise price of $1.19 to Jeanette Weidner, the company's Principal Accounting Officer and Principal Financial Officer, with a transaction date of October 29, 2026, and a cliff-and-monthly vesting schedule.